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Abstract 
Sphingolipids are fundamental to membrane trafficking, apoptosis and cell differentiation and proliferation. KDSR or 3-keto-
dihydrosphingosine reductase is an essential enzyme for de novo sphingolipid synthesis, and pathogenic mutations in KDSR result 
in the severe skin disorder erythrokeratodermia variabilis et progressiva-4. Four of the eight reported cases also had 
thrombocytopenia but the underlying mechanism has remained unexplored. Here we expand upon the phenotypic spectrum of 
KDSR deficiency with studies in two siblings with novel compound heterozygous variants associated with thrombocytopenia, 
anemia and minimal skin involvement. We report a novel phenotype of progressive juvenile myelofibrosis in the propositus, with 
spontaneous recovery of anemia and thrombocytopenia in the first decade of life. Examination of bone marrow biopsies showed 
megakaryocyte hyperproliferation and dysplasia. Megakaryocytes obtained by culture of CD34+ stem cells confirmed 
hyperproliferation and showed reduced proplatelet formation. The effect of KDSR insufficiency on the sphingolipid profile was 
unknown, and was explored in vivo and in vitro by a broad metabolomics screen that indicated activation of an in vivo 
compensatory pathway that leads to normalisation of downstream metabolites such as ceramide. Differentiation of propositus-
derived induced pluripotent stem cells to megakaryocytes followed by expression of functional KDSR showed correction of the 
aberrant cellular and biochemical phenotypes, corroborating the critical role of KDSR in proplatelet formation. Finally, Kdsr 
depletion in zebrafish recapitulated the thrombocytopenia and showed biochemical changes similar to those observed in the 
affected siblings. These studies support an important role for sphingolipids as regulators of cytoskeletal organisation during 
megakaryopoiesis and proplatelet formation. 
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Introduction 
KDSR or 3-keto-dihydrosphingosine reductase is an early, essential enzyme in the pathway of de novo sphingolipid synthesis that 
catalyzes the conversion of 3-keto-dihydrosphingosine (KDS) to dihydrosphingosine (DHS) on the cytosolic leaflet of the 
endoplasmic reticulum.1 The canonical transcript for KDSR encodes a 332 amino acid protein. The gene is widely transcribed,1-3 
consistent with the integral roles of the sphingolipid family in forming lipid rafts that facilitate membrane trafficking and in the 
regulation of fundamental cellular functions that include apoptosis, differentiation, and proliferation.4 The importance of 
sphingolipid synthesis for normal cellular functions is illustrated by the complex multisystem phenotypes of null mice for key 
enzymes or receptors in the pathway, including defective platelet activation and thrombus formation.5, 6 A pathway for de novo 
synthesis of sphingolipids in a megakaryocytic cell line has been shown, but plays a minimal role in mature platelets, which 
instead acquire essential sphingolipids by incorporating them from plasma or recycling plasma membrane sphingomyelins, both 
largely independently of KDSR.7  
Consistent with these important roles of sphingolipids, compound heterozygous variants in KDSR (Figure 1) have recently been 
identified as causal of the severe skin disorder erythrokeratodermia variabilis et progressiva 4 (EKVP4, OMIM617526), a 
condition characterised by neonatal onset of thick, scaly skin on the face and genitals and milder erythematous palmo-plantar 
scaling.8 This observation established a role for KDSR in the homeostasis of keratinisation, however it was unclear whether these 
cases had hematological pathologies. A more recent study described four probands with EKVP4 caused by KDSR variants 
accompanied by severe thrombocytopenia and platelet dysfunction in infancy.9 A reduction in plasma S1P and surface-exposed 
ceramide in human platelets, as well as diminished ceramide levels in affected skin were reported. Bone marrow morphology in 
one patient was normal and in a second one demonstrated increased megakaryopoiesis. For this patient a diagnosis of immune-
mediated thrombocytopenia was made with no response to corticosteroid treatment and minimal response to splenectomy. No 
further exploration of the molecular mechanism underlying the thrombocytopenia was undertaken.9  
Here we provide evidence that in this pedigree, KDSR plays a fundamental role in megakaryopoiesis, cytoplasmic organisation 
and proplatelet formation. We describe a pedigree in which compound heterozygous variants in KDSR segregate with severe 
thrombocytopenia and minimal or no skin involvement. We report novel phenotypes of progressive juvenile myelofibrosis in the 
propositus, who is older, and anemia in both siblings. Broad metabolic profiling complemented by targeted mass spectrometry 
assays confirm KDSR hypofunction and suggest activation of an alternative, compensatory pathway in vivo. Depletion of kdsr in 
zebrafish and studies with CD34+ stem cell- and induced pluripotent stem cell (iPSC)-derived MK show cellular and biochemical 
signatures in common with those observed in our patients, showing the mechanism by which KDSR variants mediate 
thrombocytopenia. 
 
Methods 
Recruitment and sequencing 
Following informed, written consent (ethical study approval ML3580), the propositus was recruited to the Bleeding, thrombotic 
and Platelet Disorders (BPD) domain of the NIHR BioResource-Rare Diseases study (UK Research Ethics Committee 
13/EE/0325, https://bioresource.nihr.ac.uk). Further details are provided in the supplemental Methods.  
Platelet studies 
Aggregation and transmission electron microscopy (EM) studies were performed as described previously.10  
Metabolic profiling 
Global metabolic profiling of plasma was performed by Metabolon, Inc. (Durham, NC) using the DiscoveryHD4 liquid 
chromatography tandem mass spectrometry (LC-MS/MS) platform, as previously described.11 Results of study participants were 
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compared with 496 subjects between the ages of 4 and 55 years without thrombocytopenia. A separate LC-MS platform method, 
previously described,12, 13 was used for specific confirmation of the global sphingolipid profile. Further details are provided in the 
supplemental Methods.  
Stem cell differentiation assays 
CD34+ hematopoietic stem cells (HSC) were isolated by magnetic cell sorting (Miltenyi Biotec, Bergisch Gladback, DE) from 
bone marrow aspirates from the propositus (at 5 years of age) and an unrelated control, and from peripheral blood from the 
propositus (at 8·5 years of age), his affected sister (at 5 months of age) and an unrelated control.  
In addition, expanded bone marrow- and peripheral blood- derived HSC at day 3 of differentiation were used for liquid MK 
cultures in two experiments. In the first experiment, HSC obtained from the bone marrow of the propositus were differentiated in 
parallel to a control. For the second experiment, HSC obtained from the peripheral blood of the propositus and his affected sister 
were cultured in parallel with a different control. Details of the differentiation protocols, colony assays and statistical analysis of 
MK immunostaining are provided in the supplemental Methods.  
Zebrafish analysis 
Tg(cd41:EGF) embryos14 were injected at the one-cell stage with a kdsr ATG morpholino (MO) (5’ ctcagaggacatgggtcaacctgat, 
Kdsr-MO) purchased from Gene Tools LLC (Philomath, OR) or with buffer (control). Zebrafish kdsr has ZFIN accession number 
ZDB-GENE-040426-853. Thrombocyte formation was analysed as described previously.15, 16 Immunoblots were developed with 
goat anti-GFP (Rockland) and anti-FVT1/KDSR (Clone H-149; Santa Cruz). All animal protocols were approved by the Ethical 
Committee of KU Leuven. 
Lentiviral reference KDSR transcript expression in iPSC 
iPSC were prepared by the Cambridge Biomedical Research Centre iPSC core laboratory as described in the supplemental 
Methods. iPSC were transduced with the lentiviral vector to express the open reading frame (ORF) of KDSR (pLenti-EF1a-
KDSR-myc-DDK-IRES-Puro, Origene) and the un-cloned destination vector PS10085 (Origene) to generate the reference 
transcript rescue line (Kresc) and empty vector control line (Kev), respectively. The ORF is identical to transcript 
ENST00000591902 (RefSeq accession no. NM_002035, Origene TrueClone cDNA cat. RC201153), which has the highest 
reported expression in MK.2 Details of lentiviral particle production, transduction and selection are given in the supplemental 
Methods.  
Forward programming to MK (iMK) 
iPSC were reprogrammed to MK (named iMK hereafter) using a protocol for generating MK described by Moreau et al.17 Kresc 
and Kev iMK were generated in three independent experiments. Details of iMK reprogramming, immunophenotyping, the 
proplatelet assay and RNA sequencing are given in the supplemental Methods.  
Results 
Clinical characteristics 
The eight-year old male propositus was born to healthy, unrelated parents of European ancestry (Figure 2A). At 4 months of age 
he presented with a viral infection and was found to have a platelet count of 65x109/L and mild normocytic, normochromic 
anemia with normal iron and hematinic levels (Figure 2B, supplemental Table 1A, supplemental Figure 1). Subsequent complete 
blood counts showed on several occasions platelet counts <100x109/L accompanied by rectal and gingival bleeding, excessive 
ecchymosis, and recurrent epistaxis when platelet counts were <10x109/L. Possible skin involvement was limited to a slow-to-heal 
perianal wound following rectal manometry. Serial bone marrow examinations revealed increased numbers of dysplastic MK and 
progressive severe myelofibrosis (Figure 2C, supplemental Figure 2, supplemental Table 1B); despite this we observed significant 
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fluctuation in the propositus’ thrombocytopenia and normalisation of the hemoglobin level over the course of his first decade 
(Figure 2B, supplemental Table 1A). The mechanism of the improvement is unclear, and occurred in the absence of identifiable 
environmental, therapeutic, or dietary interventions. Genetic analyses of bone marrow DNA excluded known somatic mutations 
causal of myelodysplasia or primary myelofibrosis (supplemental Table 1B). Light transmission platelet aggregation was normal 
with the exception of an attenuated response to stimulation with collagen at low dose (supplemental Table 1C). The propositus’ 
older brother and his parents were unaffected (Figure 2A). His sister presented at birth with thrombocytopenia (Figure 2A and B, 
supplemental Table 1A) and mild ichthyosis in her left axilla (Figure 2D), but the skin symptoms resolved spontaneously over the 
first month. At 5 months of age she also developed persistent, normocytic, normochromic anemia (Figure 2B, supplemental Table 
1A). Transmission EM analysis showed platelets of normal size (Figure 2E). Delta-granules appeared diminished, however it was 
not possible to count these accurately in the absence of whole-mount EM or a specific δ-granule marker (CD63 also stains 
lysosomal structures). There were no other marked ultrastructural abnormalities.     
Pathogenic variants in KDSR 
The propositus and his affected sister carry a maternally inherited nonsense variant 18:61006104 G>A (p.Arg236*) and a 
paternally inherited missense variant 18:61018270 G>A (p.Arg154Trp) in KDSR (Figure 2A). The variants were confirmed by 
Sanger sequencing (supplemental Figure 3) and have minor allele frequencies in Europeans of 4·82x10-5 and 2·32x10-4 
respectively.18, 19 The missense variant p.Arg154Trp is localised in the catalytic domain of KDSR (Figure 1)20 and both are found 
in the most abundant KDSR transcripts in MK (supplemental Figure 4).2 The nonsense variant is absent from two out of three 
major platelet transcripts, which is in keeping with minimal de novo sphingolipid synthesis in mature platelets (supplemental 
Figure 4).7 The results of co-segregation study were concordant with an autosomal recessive mode of inheritance (Figure 2A). 
Sphingolipid profiles 
We reasoned that the variants would cause reduced enzymatic function, leading to a build-up of the substrate KDS (Figure 3A). 
Indeed global metabolic profiling showed KDS to be detectable in plasma from the propositus but not from the parents, the 
healthy sibling, and 496 unrelated controls (Figure 3B). This finding was corroborated using a LC-MS platform for the selective 
measurement of specific sphingolipids, which confirmed that KDS was detectable in both patients and absent from the plasma of 
controls (Figure 3C, supplemental Figure 5). Interestingly, there was no reduction in downstream sphingolipids in the patients 
using either platform (supplemental Tables 2 and 3A). In fact, global profiling showed levels of the KDSR product, DHS, were 
higher for the propositus than controls. These findings raise the hypothesis that KDSR hypofunction during de novo sphingolipid 
synthesis is compensated in vivo by alternative mechanisms, for example by the recycling of relatively abundant sphingomyelins 
along a pathway that normally contributes little to free DHS production.4  
Depletion of kdsr in zebrafish causes thrombocytopenia 
We explored the role of the enzyme on thrombocyte formation in zebrafish by MO-mediated depletion of the kdsr transcript in 
Tg(cd41:EGFP). This led as expected to a reduction of the Kdsr protein level  (Figure 4A and B) and resulted in curved tails, 
which is a typical feature for embryos with thrombocytopenia (supplemental Figure 6).15 The number of thrombocytes was 
inversely correlated with the dose of MO injected (Figure 4C and D). Targeted sphingolipid profiling showed elevated and 
undetectable KDS in lysates from MO and control embryos, respectively (Figure 4E). Similar to the results obtained with the 
propositus’ plasma, dihydroceramides, ceramides, sphingomyelins and glycosphingolipids that are downstream of Kdsr were not 
significantly different between Kdsr-depleted and control fish (supplemental Table 3B).  
Impaired proplatelet formation in MK from patients 
CFU-GEMM cultures differentiated from bone marrow HSC of the propositus showed hyperproliferation of myeloid cells 
(p=0·001, t-test) with a reduced myeloid/erythroid ratio compared to the controls (supplemental Figure 7). CFU-MK numbers 
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were comparable to those of the control, although individual MK colonies were denser for the propositus and liquid cultures 
showed an increased number of MK (supplemental Figure 8). MK in control cultures formed proplatelets, whilst MK derived from 
both the propositus and affected sister showed a strong reduction in proplatelet formation, despite similar levels of membrane 
budding and a higher number of CD41 and CD42 positive cells in propositus-derived cultures when compared with control MK 
(Figure 5A; supplemental Figure 8, 9, and 10). Patient-derived MK also showed extensive, abnormal formation of lamellipodia 
and reduced cell size (p=0·014, likelihood ratio test, Figures 5B and C).  
The abnormal morphological, functional, and biochemical features of the propositus’ iMK can be rescued   
To corroborate the atypical phenotypes of MK derived from the HSC, we transduced iPSC from the propositus with lentiviral 
vectors containing the reference KDSR ORF (Kresc) or an inert control vector (Kev), and reprogrammed these cells to iMK 
(supplemental Figure 11A). Analysis of the iMK RNA-seq results showed similar KDSR gene expression but the majority of 
sequencing reads in the rescued iMK carried the reference allele at Chr18:61018270 G>A (p.Arg154Trp, supplemental Figures 
11B, C and D). These findings are consistent with correction of the genetic defect without significant overexpression, and resulted 
in increased proplatelet formation compared with control iMK four hours after seeding (Figures 6A, B and C; p=0·047, t-test). The 
observed iMK proplatelets were shorter and less branched than those observed following directed differentiation from stem cell 
cells, in keeping with published reports using this protocol.17 Upon microscopic inspection the rescued iMK seemed larger than 
the non-rescued ones (which was confirmed to be significant by flow cytometry, supplemental Figure 11E) and the increased 
proplatelet formation resulted by 24 hours in little residual cytoplasm for the rescued versus the non-rescued iMK (Figure 6C). At 
the biochemical level the rescue resulted in a significant reduction of KDS levels (p=0·02, t-test) showing the effectiveness of the 
gene therapy approach in ‘curing’ the iMK from the propositus (Figure 6D). Similar to findings in plasma and in zebrafish, DHS 
levels did not differ between the iMK with and without functional KDSR transcripts, indicating that the postulated, compensatory 
mechanism is also present in iMK. We searched the iMK transcriptome landscape for possible differences in the levels of 
transcripts of other key enzymes that regulate sphingolipid synthesis and recycling (the enzymes examined are as shown in Figure 
3A). This identified only ASAH1 and CERS6 transcripts to be down- and up- regulated respectively (posterior probabilities 0·610 
and 0·774; log fold change -0·67 and +0·70, respectively). These two enzymes regulate the ceramide-sphingosine ratio (Figure 3A, 
supplemental Figure 12) and in keeping with these findings, the rescued iMK showed higher sphingosine and lower ceramide 
levels (Figure 6D).  
Discussion 
Pathogenic mutations in KDSR have recently been associated with a recessively inherited syndrome of moderate-to-severe skin 
pathology and thrombocytopenia.8, 9 We have described two novel KDSR mutations causing thrombocytopenia in the propositus 
and his infant sister, expanding the phenotypic spectrum of this recently identified Mendelian disorder from severe skin pathology 
with no apparent hematological involvement to profound thrombocytopenia and moderate anemia with spontaneous improvement 
across the first decade, and almost imperceptible dermatological abnormalities. In the propositus bone marrow studies also 
showed the novel phenotype of severe juvenile myelofibrosis, however the sister was too young to allow confirmation of this 
phenotype. The biochemical sphingolipid signatures of the plasma and patient-derived iMK confirmed the predicted reduction in 
function with elevated levels of its substrate, KDS. This is as expected, from the combination of a variant encoding a premature 
stop codon and a hypomorphic allele involving a missense variant in the catalytic domain. Unexpectedly, downstream metabolites 
in the sphingolipid pathway including DHS, ceramide, and sphingosine-1-phosphate were not reduced in plasma, suggesting that 
KDSR hypofunction during de novo sphingolipid synthesis is compensated by an alternative pathway. One possible alternative 
pathway is the recycling of relatively abundant sphingomyelins, a pathway previously shown to contribute to production of 
downstream sphingolipids such as dihydroceramide, ceramide, and sphingosine, but considered to contribute little, if at all to DHS 
production under normal conditions.21 Post-translational modifications to sphingolipid enzymes may also explain the metabolic 
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profile, and further work is required to explore this possibility. Importantly, the profile of increased ceramide and reduced 
sphingosine in propositus-derived iMK compared with rescued iMK, and the consistent and potentially explanatory transcriptional 
dysregulation of enzymes ASAH1 and CERS6, is at odds with the limited sphingolipid quantitation undertaken in previous studies 
which showed that ceramide levels were reduced in affected skin and that platelet surface exposure of ceramide was impaired in 
individuals with hypo-functional KDSR variants.9  
Our observation that MK lacking functional KDSR are hyperproliferative is consistent with earlier reports,9 but we expand on this 
characterisation by showing the ex-vivo generated patient MK to be smaller than controls and to be less effective in proplatelet 
formation. Proplatelets are pseudopodial projections of megakaryocyte cytoplasm, supported at their core by microtubular bundles 
that carry granules and other platelet cargo from the body of the megakaryocyte to the tip of the proplatelet.22 Aberrant size and 
proplatelet formation were not only observed in MK obtained by differentiation of primary HSC obtained from the two patients, 
but are also present in iMK generated by forward programming of iPSC derived from the propositus’ fibroblasts. All together we 
consider the ineffective platelet formation caused by the absence of KDSR to be the primary cause of the thrombocytopenia. 
Increased turn-over because of a reduced platelet lifespan seems to be a less likely explanation because the immature platelet 
fraction was not significantly raised in the two patients compared with healthy controls (data not shown). We hypothesize that 
impaired platelet formation may, in turn, be caused by cytoskeletal disorganisation and further experiments are required to explore 
this possibility. Pathogenic mutations in several other genes (e.g. MYH9, ACTN1, FLNA, TUBB1, DIAPH1, TPM4) encoding 
proteins with important functional roles in cytoskeletal reorganisation and actin polymerisation are causal of dominant forms of 
thrombocytopenia.23 However these genetic disorders are characterised by enlarged platelets, and the mean volumes of the 
platelets of our patients are within the normal ranges for males and females, respectively.  
The increased level of KDS in plasma was confirmed at the cellular level in iMK derived from the propositus. This increased level 
was normalised upon rescue of the propositus’ iMK with a KDSR transcript carrying the reference allele. The correction of the 
biochemical defect was mirrored by a recovery of iMK size and improvement of their capacity to form proplatelets.  In further 
support of the central importance of KDSR in thrombopoiesis we show that KDSR knockdown in a zebrafish model is associated 
with impaired thrombocyte formation. Similar approaches have identified multiple potential regulators of thrombopoiesis,24 
though in isolation zebrafish studies are limited by inherent differences in thrombopoiesis between mammals and fish, notably that 
zebrafish have nucleate thrombocytes rather than MK. 
The marked, spontaneous improvement of the propositus’ thrombocytopenia and anemia led to reversal of the decision to treat the 
condition by HSC transplantation. The mechanism of this improvement is unclear, given the presence of progressive 
myelofibrosis and in the absence of clinical features to suggest significant extramedullary hemopoiesis such as splenomegaly. 
Recent studies have shown spontaneous improvement in blood counts in other inherited juvenile bone marrow failure syndromes, 
most notably those associated with pathogenic variants in SAMD9 or SAMD9L.25 In these cases the improvement was attributed to 
the acquisition of corrective somatic mutations. Further longitudinal studies of individuals affected by pathogenic KDSR variants 
is essential to determine whether the clinical course described is representative, and whether a careful watch-and-wait approach 
rather than early intervention may be more appropriate in this genetically-defined subgroup of cases with inherited 
thrombocytopenia accompanied by bone marrow failure.  
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Figure 1. Reported KDSR variant genotypes and phenotypes in the context of KDSR structure and function 
Protein and cDNA schematic adapted from Gupta et al20 demonstrating location of known pathogenic KDSR variants with documented 
phenotypes in skin only (black), skin and platelets (red) and the novel variants reported in this manuscript in bold and underlined. Variants are 
linked by brackets where present in compound heterozygosity in an individual. Key structural elements of KDSR are illustrated: transmembrane 
anchors (blue, purple), the Rossman folds (red), and a highly conserved domain containing three putative catalytic sites (yellow). The novel 
p.Arg154Trp variant is within the catalytic domain. 
 
Figure 2. Clinical characteristics associated with loss-of-function KDSR variants 
(A) Pedigree and variants identified in KDSR. ‘+’ denotes the major allele. The propositus and affected sibling, 
but not the healthy sibling, carry the missense variant 18:61018270 G>A (p.Arg154Trp) and the nonsense variant 18:61006104 G>A 
(p.Arg236*). Co-segregation analysis demonstrated that the father carries the former and the mother the latter variant. (B) Serial blood counts 
are shown for the two affected siblings and a single value for the healthy brother. Fluctuating anemia and thrombocytopenia was observed, 
without evidence of neutropenia. (C) Bone marrow biopsy. Left: Numerous dysplastic megakaryocytes made visible with LAT staining are 
present. Right: Marrow fibrosis with strong stromal reticulin staining. Magnification x40. Further images can be found in the supplemental 
materials. (D) The affected sibling was born during the course of this study and presented at birth with thrombocytopenia and mild ichthyosis in 
her left axilla. The skin symptoms improved spontaneously over the first month. (E) Platelets were examined by electron microscopy for an 
unrelated healthy control, the propositus, and the affected sibling. There were no marked morphological differences. Arrowed magnifications 
show δ-granules. Magnification 12,000x.  
 
Figure 3. Metabolic profiling shows that the KDSR variants are associated with loss-of-function and downstream sphingolipid pathway 
compensation  
(A) Simplified sphingolipid pathway highlighting the role of the KDSR enzyme in de novo synthesis (black arrows) and the generation of 
sphingolipid intermediates from the recycling of complex sphingolipids and sphingomyelins (green arrows). (B) Mass spectrometry using the 
Metabolon platform shows the major chromatographic peak of 3-keto-dihydrosphingosine (KDS) in the plasma of the propositus, but not of the 
unaffected pedigree members (shown) or the controls (not shown). (C) KDSR hypofunction was confirmed in the propositus and affected sister 
using a second mass spectrometry platform for targeted sphingolipid profiling. The chromatogram shows that KDS was detected in the plasma 
from the propositus and his affected sister but not in the plasma from the healthy brother, parents (shown), and two controls (not shown).  
 
Figure 4. Kdsr morpholino knockdown is associated with reduced thrombopoiesis in zebrafish 
(A) Tg(cd41:EGF) embryos were injected with a kdsr ATG-MO (1000 µM) or with buffer (control). Embryos were lysed 72 hpf and used for 
immunoblotting. GFP and Kdsr proteins were reduced in the kdsr knockdown condition. Equal amounts (50 μg) were loaded (5 randomly 
selected embryos for each of the 4 conditions). Staining of Gapdh was used as loading control. (B) Quantification of immunoblot after 
normalization for Gapdh. Mean values are plotted and error bars show the standard deviation, analysed by one-way ANOVA. (C) Quantification 
by flow cytometry of the number of GFP-labelled thrombocytes in Tg(cd41:EGFP) Danio rerio embryos at 72 hpf for kdsr-MO (800 or 1000 
µM) or buffer (control) injected fish. Values are means and standard deviations (SD) as quantified for 10 randomly selected embryos for each 
condition, performed in triplicate. Results were analyzed by one-way ANOVA. (D) Greyscale stereo-microscope images (20x original 
magnification) in the tail region at 72 hpf showed a reduced number of GFP-labelled thrombocytes (in white). (E) KDS levels in lysates from 72 
hpf embryos (20/condition) for kdsr-MO (800 µM) or buffer (control) injected fish. KDS was detected in the lysates from the MO-injected 
embryos but not in the control-injected embryos.  
 
Figure 5. KDSR variants are associated with reduced proplatelet formation by megakaryocytes (MK)  
(A) Quantification of proplatelet formation by MK at day 11 of differentiation. On the left are the results of differentiation of bone marrow-
derived hematopoietic stem cells (HSC) from the propositus and control. On the right are the results of differentiation of HSC obtained from the 
blood of the propositus, his affected sibling and a second control. All MK with proplatelets and membrane budding were counted as positive. 
Values plotted are means and standard deviations (SD) as quantified on 20 images. Results were analyzed by the unpaired, two-tailed t-test. (B)  
MK at day 11 derived from bone marrow HSC from the propositus and a control. MK are stained for the cytoskeletal marker F-actin (red) and 
lysosome and δ-granule marker CD63 (green). MK from the propositus and affected sibling have irregular cytoskeletal structures with 
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lamellipodia (arrows). Further images can be found in supplemental Figure 10. (C) MK area was quantified by automated analysis. Modelling 
was performed using a linear mixed effects model and associated p-values were computed by a likelihood ratio test. MK from affected cases 
were smaller compared to unrelated controls (p=0·01473).  
 
Figure 6. KDSR reference allele expression rescues ineffective proplatelet formation 
Proplatelet formation by iMK. 100% of live MK plated for the proplatelet assay were CD41 positive and 75% were dual positive for CD41 and 
CD42 by flow cytometry (supplemental Figure 11A). Cytoskeletal marker α-tubulin was stained with antibodies in green and nuclei were stained 
with DAPI in blue. Proplatelet formation was counted manually. Values shown were analyzed using the paired, two-tailed Student’s t-test, using 
p<0·05 for significance and are plotted as means and standard deviations. (A) The number of proplatelets formed at 4 hours per proplatelet-
forming MK (PPFMK) by the rescued and non-rescued iMK. The differences were significant at 4 hours (p=0·047) but not anymore at 24 hours 
(p=0·20). (B) The number of PPFMK at 4 hours did not differ significantly between the two groups (7·1% vs 42·4% , p=0·10), but at 24 hours 
the rescued showed less PPFMK (p=0·03). (C) Representative images from the proplatelet formation assay at 4 and 24 hours. Proplatelets are 
indicated by white arrows. Top left and right panel: Results at 4 hours for rescued iMK show increased proplatelet formation. White scale bars 
indicate 10µm. Bottom left and right panel: Results at 24 hours show little proplatelet formation for the rescued iMK, and residual cells are 
either fragmented into platelet-like particles, or consist of bare nuclei. (D) Metabolon mass spectrometry results for non-rescued and rescued 
iMK. The ion counts for KDS detection differed significantly between the non-rescued and non-rescued iMK (p=0·02). The DHS level did not 
differ between the groups of samples but the levels of sphingosine and ceramide were lower and higher in the non-rescued versus rescued iMK, 
respectively. 
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Supplemental Materials 
 
Supplemental Methods 
Recruitment and sequencing 
Genetic variants were identified from whole genome sequencing (WGS) data using Isaac (Illumina Inc.) or as 
described previously for whole exome sequencing.1 Clinical and laboratory phenotypes were recorded in raw 
form and as Human Phenotype Ontology (HPO) terms along with pedigree data.1 The propositus’ genetic and 
phenotypic data were analyzed as part of a dataset of from 9,472 study participants that have undergone genetic 
analysis, which includes 1,472 cases with unexplained BPDs. 
Platelet imaging  
Platelet imaging was performed using a structured illumination microscope (SIM, Elyra S.1, Zeiss, Heidelberg, 
DE). Images were analyzed with ZEN Black (Carl Zeiss Inc., Oberkochen, DE) and ImageJ software (National 
Institutes of Health (NIH), Bethesda, MD).2 Raw 3D SIM images were processed to super-resolution SIM using 
ZEN Black software, followed by maximum intensity projection as previously described.3  
Metabolic profiling 
In the targeted sphingolipid profiling protocol, for the identification of KDS we used a Thermo Scientific Q-
Exactive Orbitrap (ThermoFisher Scientific, Hemel Hempstead, UK) set up to fragment the 300.3 ion (±2 m/z) 
using a relative collision energy of 30. The KDS standard used was purchased from Matreya LLC (Cat. no. 
1876, State College, PA). All samples were snap frozen in dry ice and stored at -80ͼC until analysed. Zebrafish 
lysates for sphingolipid profiling were prepared as for immunoblot analysis, using 20 embryos per condition, in 
triplicate, isolated at 72 hours post fertilisation [hpf].4 
Stem cell differentiation assays 
CD34+ hematopoietic stem cells (HSC) isolated from bone marrow aspirates from the propositus (at 5 years of 
age) and an unrelated control, and from peripheral blood from the propositus (at 8∙5 years of age), his affected 
sister (at 5 months of age) and an unrelated control were stored in liquid nitrogen. The recovered (differentiation 
day 0) CD34+ HSCs were cultured in StemSpan SFEM medium with StemSpan CC100 ensuring strong 
expansion of HSC for 3 days (Stem Cell Technologies, Vancouver, CA). 
The expanded bone marrow derived HSC were used to perform colony assays for MK (CFU-MK) and 
granulocytes, erythrocytes, monocytes, and MK (GEMM; CFU-GEMM) as described previously.4, 5 These were 
performed in quintuple for MegaCult-C 04973 (MK) and triplicate for MethoCult 04964 (GEMM, StemCell 
Technologies, Vancouver, CA). MK (after Giemsa staining) and GEMM (without staining) colonies were 
counted by two independent operators using a Zeiss Axiovert 200M microscope (Carl Zeiss Inc.) or light 
microscope (Leica DM RBE, Wetzlar, DE), respectively. Colonies from GEMM plates were further analysed by 
flow cytometry using FITC-labelled mouse antibodies against glycophorin A (CD235a; BD Biosciences, San 
Jose, CA) and PE-labelled mouse antibodies against CD45 (Clone T29/33; Dako, Glostrup, DK). 
Liquid MK cultures were derived from bone marrow- and peripheral blood- derived HSC at day 3 of 
differentiation by incubation with 50ng/ml thrombopoietin (TPO), 25ng/ml stem cell factor, and 10ng/ml 
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interleukin 1β (Peprotech, Rocky Hill, NJ,). MK were analysed by flow cytometry on total differentiation day 7 
with FITC-labelled antibodies against CD41 and CD42 (BD Biosciences) and on total differentiation day 11 for 
proplatelet formation and immunostaining of cytoskeletal proteins F-actin, phalloidin-rhodamine (Sigma, St 
Louis, MO), and anti-tubulin (ThermoFisher Scientific), and δ-granule and lysosome marker CD63 (Santa Cruz, 
Dallas, TX).5, 6 For immunostaining MK were seeded for 4 hours on fibrinogen-coated coverslips and stained 
cells were photographed at 63x magnification with a confocal microscope (AxioObserver.Z1, Zeiss, Heidelberg, 
DE). MK cell size was determined by F-actin staining and images were analyzed with ImageJ software (NIH2). 
Three random control images were used to optimize parameters and MK were excluded if the ploidy was 
unclear following F-actin staining, as described.7  
Statistical analysis of MK size following immunostaining 
Using the lmer function from the R package lme4 a linear mixed effects model was fitted to the log of MK cell 
size: 
ݕ௜௝௞௟ ൌ ߙ ൅ ߚ݌௜௝௞ ൅ ᖤݏ௜ ൅ ߦ ௝݂ ൅ ߜ݌௜௝௞ݏ௜ ൅ ߟ௜ ൅ ߳௜௝௞௟ 
ߟ௜ ׽ ܰሺͲǡ ߪఎ
ଶሻ 
߳௜௝௞௟ ׽ ܰሺͲǡ ߪఢ
ଶሻ 
where ݕ௜௝௞௟ corresponds to the kth observation for individual i א {1,2,3,4} obtained as part of experiment j 
א{1,2}. The covariate ݌௜௝௞is equal to 0, 1 or 2 depending on whether the ploidy was 1, 2 or between 4 and 8, 
respectively. The covariate ݏ௜equals 1 if individual i is a case and 0 otherwise. The covariate ௝݂ equals 1 if j=2 
and 0 if j=1. The interaction term ߜ captures the difference in the ploidy-dependent slope between cases and 
controls. Inter-individual variation is modelled with normally distributed random effects (ߟ௜).  
The regression coefficients ߙොǡ ߚመǡ ᖤොǡ ߦመǡ ߜመwere estimated by maximum likelihood and associated p-values were 
computed by a likelihood ratio test and were as follows: 
MK cell size:  ߙො ൌ ͹Ǥ͹ͺͲ͹ͷ 
   ߚመ ൌ ͲǤ͵ͷͶͻ͸ 
   ᖤො ൌ െͲǤͶʹͶͶ͵  p = 0.01473 
   ߦመ ൌ െͲǤͲͷ͸͵ʹ   
   ߜመ ൌ ͲǤͲ͹ͳͻ͹  p = 0.2641 
iPSC derivation  
iPSC were prepared by the Cambridge Biomedical Research Centre iPSC core laboratory from fibroblasts 
isolated from a 2mm skin biopsy of the propositus’ upper arm. Fibroblasts were reprogrammed following the 
protocol of Yamanaka and colleagues8, 9 by overexpression of transcription factors OCT4, SOX2, KLF4, and c-
MYC using the CytoTune™-iPS 2∙0 Sendai Reprogramming Kit (Invitrogen) followed by culture on mouse 
embryonic fibroblast feeder cells in chemically defined media. Following establishment of iPSC colonies, 
approximately one month after reprogramming, clones were picked, passaged to feeder-free conditions, and 
validated. iPSC were cultured feeder- and antibiotic- free in Essential 8 medium (ThermoFisher Scientific). 
Lentiviral particle production, transduction and selection 
Replication-deficient lentiviral vector particles were produced by transient co-transfection of HEK 293T cells 
with the rescue or empty vector and a 2nd generation packaging system consisting of psPAX2 and pCMV-VSV-
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G (Addgene #12260, #8454). Viral particles were concentrated by the LentiX-concentrator system (Clontech). 
Transduction was performed in iPSC at MOI 2, in the presence of protamine sulphate 10μg/ml (Sigma) and was 
followed by plate centrifugation at 2500 rpm for 45 minutes at 37ͼC. Cells carrying the rescue or empty vector 
were selected after 72 hours using 0∙1μg/ml puromycin (Sigma).  
Forward programming to MK (iMK) 
Passage to single iPSC was obtained using TrypLE (ThermoFisher Scientific) followed by culture in Essential 8 
media containing 10µM ROCK inhibitor (Sigma) for 24 hours prior to lentiviral transduction with FLI1, 
GATA1, and TAL1 using a protocol for generating MK described by Moreau et al.10 The MK obtained by this 
protocol (named iMK hereafter) were defined at day 20 post-transduction by absence of staining with 1μg/ml 
DAPI (Sigma; at this concentration live iMK are impermeant to DAPI) and dual staining with anti-CD41a-APC 
and anti-CD42b-PE (1:100, cat. 559777 and 1:1000, cat. 555473, respectively, BD Biosciences) on the 
Beckman Coulter Gallios Cytometer. Cytometry results were analysed using Kaluza Analysis v.1.5a (Beckman 
Coulter). 
Proplatelet assay  
iMK were placed at a concentration of 0∙5x106/ml in CellGro medium (CellGenix) for seeding on sterile glass 
coverslips coated with 200µg/ml fibrinogen (Sigma) in phosphate-buffered saline (PBS). Cells were fixed in 1% 
paraformaldehyde at 4 hours or 24 hours after seeding. Cells were quenched with 50µM ammonium chloride 
and permeabilized with 0∙1% saponin, 0∙2% gelatin, and 0∙02% azide (Sigma) in PBS. Staining was performed 
with antibody against α-tubulin (1:250, cat.T5168, Sigma), 1μg/ml DAPI (Sigma), and goat anti-mouse Alexa 
Fluor 488 antibody (1:1000, cat. A21121, ThermoFisher Scientific). Cells were examined within 48 hours using 
a Leica DMi8 fluorescent microscope and images were analysed using FIJI software.2 Five to ten representative 
fields were examined to ensure at least 100 iMK were observed for each experimental condition. Proplatelets 
were defined as clear projections from the main cell body with approximately parallel sides to the shaft. Results 
were compared using the paired, two-tailed Student’s t-test.  
RNA sequencing 
1 x 105 iMK were stored in 500 µl Trizol reagent (ThermoFisher Scientific) at -80ͼC. RNA was recovered for 
sequencing (RNA-seq) with the Direct-zol RNA MiniPrep kit (Zymo). RNA was quantified using the Qubit 
RNA HS Assay kit (ThermoFisher Scientific) and its quality was confirmed using the Agilent RNA 6000 Pico 
kit on the Agilent 2100 Bioanalyzer.  cDNA libraries were prepared using the KAPA Stranded RNA-Seq Kit 
with Riboerase (Roche) and Agencourt AMPure XP beads (Beckman Coulter) for purification. Libraries were 
quantified by RT-qPCR with the KAPA Library Quantification Kit (Roche). Libraries were sequenced at the 
Cancer Research UK Cambridge Institute Genomics Core) on a HiSeq4000 (Illumina Inc.) using 150bp read 
length paired-end sequencing. Sequences were aligned with STAR11 and read counts were obtained using 
featureCounts12 with respect to Ensembl v.70 of reference genome build GRCh37. Expression of transcripts and 
genes was quantified using MMSEQ and differential expression was assessed using MMDIFF13, 14. The prior 
probability of differential expression was set to 0∙1 and a posterior probability >0∙5 was used to declare a 
transcript being differentially expressed.  
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Supplemental Table 1: Clinical data  
 
(A) Serial blood results for propositus and pedigree members. Abnormal results are shown in bold. Spontaneous 
improvements in both platelet count and hemoglobin level were observed in the propositus, though the improvement in 
platelet count was not sustained. The affected sibling’s platelet count and haemoglobin values have been decreasing 
since birth.  
 WBC 
(x109/L) 
Neutrophils 
(x109/L) 
Erythrocytes 
(x106/L) 
Reticulocytes  
(x109/L) 
Immature 
reticulocyte 
fraction (%) 
Hemoglobin 
(g/dL) 
Platelets 
(x109/L) 
Control values Neonates  
(<6 months) 5.5-21 
1.5-10 3.9-6.3 20-100 5-21 13.5-21.5 150-550 
Control values Adults  
(> 7 year) 4.5-13.5 
1.5-8.5 4-5.2 20-100 5-21 11.5-15.5 150-450 
Control values Children 5.5-15.5 1.5-8.5 3.9-5.3 20-100 5-21 11.5-13.5 150-550 
Father 5.9 3.21 4.88 ND ND 15.5 258 
Mother 5.22  2.94 4.25 ND ND 12.8 415 
Healthy brother,  4 years 5.04 1.59 3.94 ND ND 11.5 521 
Propositus, 4 months 11.3 5.9 3.8 19 ND 10.6 65 
Propositus, 1 years 8.85 3.8 3.91 45 18.2 10.0 65 
Propositus, 2 years 10.98 4.7 3.94 43 25.4 10.2 64 
Propositus, 3 years 10.22 3.3 3.78 39 27.2 10.3 60 
Propositus, 4 years 7.84 3.9 3.41 27 39.3 9.1 9 
Propositus, 5 years 14.53 9.7 3.69 56 32 10.7 41 
Propositus, 6 years 7.61 2.9 3.77 14 22.2 10.6 15 
Propositus, 8 years 7.06 3 4.67 25 7.8 13.6 77 
Propositus, 8.5 years 9.49 4.4 4.24 37 9.7 12.5 152 
Propositus, 9 years 7.89 3.9 4.2 36 10.6 12.5 132 
Propositus, 9.5 years 9.97 5.6 4.72 40 10.4 13.4 113 
Affected Sister,  1 week 11.64 3.4 5.73 25 16.1 19.1 73 
Affected Sister,  5 months 9.34 2.2 3.33 45 24.7 8.6 148 
Affected Sister,  7 months 10.15 3.8 3.2 34 22.2 7.8 124 
Affected Sister, 9 months 13.18 5.5 3.2 72 32.1 7.7 107 
Affected Sister, 1 year 14.58 4.1 2.67 76 41.6 6.3 24 
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(B) Serial assessments of peripheral blood films and bone marrow biopsies in the propositus.  
 
 Peripheral blood smears Bone marrow biopsy Bone marrow genetics 
II:2 (Propositus) 4 
years 
White blood cells normal, mild 
normocytic normochromic anemia 
with mild aniso-poikilocytosis and 
severe thrombocytopenia.   
Erythrophagocytosis. Dysplastic 
megakaryocytes that are located in clusters. 
Normal lymphoid lineage with granulocytes. 
Myelofibrosis grade 2 reticulin staining. 
Negative: BCR-ABL, FISH 
(monosomy 7), JAK2, 
CALR and MPL, 
chromosomal breakage 
II:2 (Propositus) 5 
years 
Mild monocytosis and neutrophilia , 
mild normocytic normochromic 
anemia with anisopoikilocytosis and  
obvious thrombocytopenia 
Left-shifted myeloid lineage. Increased 
numbers of dysplastic megakaryocytes. 
Erythroid lineage difficult to study due to 
insufficient numbers. Myelofibrosis grade 3. 
Cellularity 90%, myeloid/erythroid: 4/1. 
 
II:2 (Propositus) 8 
years 
Mild poikilocytosis and 
thrombocytopenia. 
Normal cellularity 70-80%. Normocellular 
but hyperplastic  and left-shifted myeloid 
lineage. Prominent hyperplastic  
megakaryocyte lineage with strong cluster 
formation on LAT staining. Megakaryocyte 
dysplasia with both hyperlobulated and small 
hypolobulated, hyperchromic cells. 
Normocellular erythroid lineage without 
dysplasia. Myelofibrosis grade 3. 
Mason trichrome staining of bone marrow 
showed mature collagen fibers (grade 3).  
Negative: NGS panel test 
TruSight Myeloid 
Sequencing (Illumina) with 
coverage of 500x.  FISH 
with normal karyotype.  
 
(C) Platelet light transmission aggregometry studies. 
 
The propositus had normal aggregation responses for ristocetin (105%), arachidonic acid (95%), U46619 
(111%), collagen at 2 μg/ml (70%) and ADP at 5 μM (97%). Only the response to low dose of collagen was 
mildly reduced. 
 
 Propositus* Two unrelated healthy controls* 
Amplitude for Horm collagen 1μg/ml 25% 63 and 66% 
Amplitude for ADP 2.5 μM 52% 48 and 28% 
*All aggregations were performed using platelet-rich plasma at 90x103 platelets/μL. 
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Supplemental Table 2 
Ion counts from Metabolon analysis of plasma sphingolipids from the propositus, healthy brother, 
parents, and 496 unrelated controls.  
3-ketosphinganine (KDS) was detectable in only the propositus. Downstream metabolites were not reduced, and 
the enzymatic product of KDSR dihydrosphingosine (DHS) was in fact unexpectedly high. NF, not found 
 
  
Propositus Healthy 
brother 
Mother Father Median 
(controls) 
S.D (controls) 
 KDS 8.5 E5 NF NF NF NF NF 
 DHS 3.6 E5 NF NF NF 6.7 E4 3.2 E4 
Dihydroceramide 6.3 E5 2.5 E5 3.3 E5 2.6 E5 3.1 E5 1.8 E5 
Sphinganine-1-phosphate 6.7 E5 4.0 E5 4.6 E5 3.4 E5 3.9 E5 1.4 E5 
Ceramide 3.5 E6 2.8 E6 3.6 E6 2.9 E6 2.8 E6 7.9 E6 
Sphingosine 1.8 E5 9.5 E4 1.0 E5 6.2 E4 1.5 E5 8.3 E4 
Sphingosine 1-phosphate 3.4 E6 2.7 E6 3.1 E6 2.3 E6 2.6 E6 6.2 E5 
Total sphingomyelins 1.3 E9 1.2 E9 1.2 E9 1.3 E9 1.2 E9 1.8 E8 
Total glycosphingolipids 1.2 E7 1.2 E7 8.9 E7 1.2 E7 1.0 E7 2.6 E6 
Phosphoethanolamine 1.6 E6 1.7 E6 1.1 E6 8.0 E5 1.6 E6 6.1 E5 
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Supplemental Table 3 
Ion counts from targeted sphingolipid analysis by LC-MS 
 
(A) Plasma sphingolipid analysis by LC-MS. Metabolites downstream of KDSR were not reduced in affected 
individuals (propositus, affected sister) compared with unaffected individuals (healthy brother, parents and 
controls). DHS, sphingosine and S1P are not measurable by this method. Differences were analyzed using the 
paired, two-tailed Student’s t-test, using p<0.05 for significance. 
 
 
 
(B) Analysis of zebrafish protein lysates by LC-MS. Metabolites downstream of Kdsr were not significantly 
different between kdsr-ATG morpholino targeted fish (800μM) and controls. Differences were analyzed using 
the paired, two-tailed t-test, using p<0.05 for significance.  
 
Zebrafish protein 
lysate Control 1 Control 2 Control 3 kdsr-ATG 1 kdsr-ATG 2 kdsr-ATG 3 p 
Dihydroceramides 1.02 E3 2.31 E3 8.31 E4 5.98 E4 3.26 E4 5.23 E4 0.16 
Ceramides 3.67 E3 9.43 E3 3.07 E3 3.43 E3 1.46 E3 3.82 E3 0.33 
Glycosphingolipids 5.11 E5 0.00 4.40 E5 3.26 E5 5.28 E5 1.01 E4 0.19 
Sphingomyelins 2.05 2.06 2.02 2.06 1.64 2.34 0.91 
 
 
 
  
Plasma Propositus Affected Sister 
Healthy 
Brother Mother Father Control 1 Control 2 p 
Dihydroceramides 3.78E-3 6.06E-3 3.90E-3 3.21E-3 2.60E-3 2.34E-3 8.46E-3 0.52 
Ceramides 2.34E-2 8.70E-3 7.21E-3 6.48E-3 8.66E-3 5.64E-3 1.37E-2 0.5 
Glycosphingolipids 1.78E-3 1.05E-3 1.69E-3 1.85E-3 1.98E-3 1.64E-3 4.04E-3 0.56 
Sphingomyelins 11.7 5.26 9.31 9.01 11.3 4.17 11.5 0.74 
Supplemental Figure 1
Peripheral blood smears from the propositus taken at 6 years of age 
Dysmorphic erythrocytes with poikilocytosis including (A) tear drop cells and (B) thrombocytopenia with platelets of 
normal volume are shown (magnification x100). 
A
B
8
AB
Supplemental Figure 2
Bone marrow (BM) biopsies from the propositus
(A) BM biopsy at 4 years of age. Left: Dysplastic megakaryocytes (MK) forming unusually large clusters. Right: Fibrosis with reticulin 
staining. (B) BM biopsy at 8 years of age. Left and right upper: Dysplastic MK in clusters. Left lower: Marrow fibrosis with strong 
stromal reticulin staining (magnification x40).
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Supplemental Figure 3
Sanger sequencing confirms putative pathogenic KDSR variants
Two rare variants (18:61006104 G>A and 18:61018270 G>A) were confirmed by Sanger sequencing in the proband and his affected 
sister. The healthy brother carried the major allele for both variants.
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Supplemental Figure 4
Heatmap of KDSR transcripts in MK and platelets (Plt)
Transcripts present at >0∙5 log FPKM (fragments per kilobase of transcript per million mapped reads) are shown and schematically repre-
sented. Key structural elements and variant annotation are as defined in Figure 1. The variants present in the affected siblings are highlight-
ed in bold, and are present in the major transcripts present in MK (ENST00000406396, ENST00000591902) but not platelets 
(ENST00000592327, ENST00000590056, http://blueprint.haem.cam.ac.uk).8 This is in keeping with previous reports that de novo sphingo-
lipid synthesis plays a minimal role in mature platelets.9 
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3-KDS Standard
 Propositus plasma KDS signal
Supplemental Figure 5
Mass spectrum of 3-KDS in propositus and standard
An LC-MS platform was used to confirm the metabolic phenotype in the propositus and affected sister. The MS2 spectrum is shown 
for the 3-KDS biochemical standard and the propositus, showing conformity of peaks. FTMS, Fourier transformation mass spectrome-
try; +pESI, positive mode electrospray ionisation; HCD, higher energy collisional dissociation. Set at the specific fragmentation of ion 
300∙3 m/z by HCD at a relative energy of 30%, obtaining data from the range 50 to 325 m/z.
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Supplemental Figure 6 
Zebrafish experiments
Tg(cd41:EGF) embryos were injected with a kdsr ATG-MO (1000 µM) or with buffer (control). At 72 hpf most embryos 
developed curled tails but no other dysmorphisms.
Control kdsr_MO 800uM 
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Supplemental Figure 7 
Myeloid stem cell differentiation assays from propositus at 5 years of age
(A, B) Representative images of CFU-GEMM colonies counted at day 10 of differentiation of CD34+ bone-marrow HSC. There 
was a higher number and increased density of colonies for the propositus compared with controls. Means and standard deviations 
of three experiments are shown. (C) Flow cytometry analysis following staining with anti-CD45 and anti-CD235 antibodies to 
stain the myeloid and erythroid lineage, respectively. The proportion of myeloid leukocytes was higher in control cultures, whilst 
cultures from the propositus were enriched for erythroid progenitors. 
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Supplemental Figure 8
Megakaryocyte colony assays
(A) MegaCult cultures. Representative images of CFU-MK colonies at day 11 of differentiation of CD34+ bone-marrow HSC. We 
observed an increased density of colonies for the propositus compared with controls. (B) However the total number of MK colonies 
was comparable between conditions. Means and standard deviations of 5 experiments are shown. (C) Liquid MK cultures were 
analysed at day 7 of differentiation using flow cytometry. A higher number of cells expressed mature MK markers CD41 and CD42 in 
cultures derived from the propositus compared with controls. FSC, forward scatter. 
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Supplemental Figure 9
Liquid megakaryocyte cultures show impaired proplatelet formation
(A) MK proplatelet formation was measured at day 11 of differentiation using bone marrow-derived CD34+ HSC from the propositus 
and controls. Propositus-derived MK were unusually large and displayed reduced proplatelet formation. (B) MK proplatelet formation 
was measured at day 12 of differentiation using peripheral blood derived CD34+ HSC from the propositus and affected sister. Again, 
MK from the patients were large and displayed membrane budding (arrows) but did not form normal proplatelets. Scale bars indicate 50
μm.
 
16
Supplemental Figure 10
Immunostaining of CD34+ stem cell-derived  megakaryocytes confirm impaired proplatelet formation, and show abnormal 
cytoskeletal organisation 
Megakaryocytes derived from bone marrow (BM) or peripheral blood (PB) were spread on fibrinogen and immunostained with 
antibodies against cytoskeletal marker F-actin (red) and δ-granule marker CD63 (green). MK for the propositus and his affected sibling 
showed irregular cytoskeletal structures that resembled filopodia (*). Proplatelet formation was infrequent and observed proplatelets 
demonstrated reduced δ-granule trafficking (arrow). Scale bars indicate 20μm. 
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Supplemental Figure 11
Gene expression analysis by RNA-seq in Kresc and Kev iMK is consistent with correction of the genetic defect, without significant overexpression
(A) iPSC from the propositus were transduced with lentiviral vectors containing the reference KDSR ORF (Kresc) or an inert control (Kev), then reprogrammed to iMK. Single, viable cells were 
assessed by flow cytometry for markers of iMK at day 20 of forward programming. In both conditions the majority of cells were CD41+ and CD42+, in keeping with differentiation to iMK. 
(B) KDSR expression was assessed by RNA-seq. At the gene level there was no significant difference in normalised KDSR expression between propositus-derived iMK (Korig), Kev and Kresc 
iMK. (C) At the transcript level ENST00000591902 was differentially expressed and higher in Kresc iMK. This transcript corresponds to the KDSR sequence in the wild-type expression vector 
and is the transcript with the highest expression in MK.8 A posterior probability of differential expression > 0∙5 was considered significant. (D) Kresc iMK carried the reference allele at 
Chr18:61018270 G>A (p.Arg154Trp) (mean count G: 192 (84%), A: 36 (16%), p = 0∙0015 by paired, two-tailed t-test). Kev iMK expression was consistent with heterozygosity (mean count G: 
14 (33%), A: 29 (67%), p = 0∙25). Values plotted are mean number of transcripts and error bars show the standard deviation, across three independent experiments. (E) iMK were defined by 
flow cytometry as CD41+ viable, single cells and forward scatter area (FSC-A) was measured for each experimental replicate. The means and standard deviations of FSC-A are plotted for the 
three experimental replicates. At day 20 Kresc iMK were significantly larger than Kev iMK (p = 0∙015 by paired, two-tailed t-test). 
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Supplemental Figure 12
Differential expression of ASAH1 and CERS6 between Kresc and Kev suggests that KDSR variants result in ceramide and 
sphingosine imbalance
Gene expression was assessed by RNA-seq. Using a posterior probability of differential expression > 0.5 for significance, only two of 
the sphingolipid enzymes listed in Figure 4A were significantly differentially expressed between Kresc and Kev.  ASAH1 (posterior 
probability = 0∙61, estimated log fold change = -0∙67) was down-regulated in the Kev condition and CERS6 
(posterior probability = 0∙774, estimated log fold change = +0∙70) was up-regulated in the Kev condition. ASAH1 and CERS6 act in 
opposition to regulate the balance between ceramide and sphingosine. These findings are in keeping with the metabolic profile of 
higher sphingosine and lower ceramide in Kresc iMK compared with Kev iMK shown in Figure 7. 
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